ReviewVirchows Archiv : an international journal of pathology2012
Personalized cancer medicine and the future of pathology.
Review in Virchows Archiv : an international journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Development of model for identifying homologous recombination deficiency (HRD) status of ovarian cancer with deep learning on whole slide images.Journal of translational medicine · 2025Article
- Highlights from the 7th Oncological Pathology Conference 'Pathological Anatomy in the context of the National Cancer Law: An overview of the Latin American experience', 15, 22 and 23 July 2022, Trujillo, Peru.Ecancermedicalscience · 2022Article
- Article
- Pathology of infectious diseases: what does the future hold?Virchows Archiv : an international journal of pathology · 2017Review
- Personalized medicine in Europe: not yet personal enough?BMC health services research · 2017Review
- Omics Profiling in Precision Oncology.Molecular & cellular proteomics : MCP · 2016Review
- Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis.American journal of nuclear medicine and molecular imaging · 2016Article
- Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Journal of the National Cancer Institute · 2014Article
- [What place and what future for the pathology of infectious and tropical diseases in France?].Annales de pathologie · 2014Review
- Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics.Frontiers in oncology · 2014Review
- [Ways to personalized medicine for gastric cancer].Der Pathologe · 2013Review
- Personal genomes, quantitative dynamic omics and personalized medicine.Quantitative biology (Beijing, China) · 2013Article
- Driving forces behind the past and future emergence of personalized medicine.Journal of personalized medicine · 2013Article
- DNA qualification workflow for next generation sequencing of histopathological samples.PloS one · 2013Article
- Systems biology: personalized medicine for the future?Current opinion in pharmacology · 2012Review
- Promise of personalized omics to precision medicine.Wiley interdisciplinary reviews. Systems biology and medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In February 2011, a group of pathologists from different departments in Europe met in Zurich, Switzerland, to discuss opportunities and challenges for pathology in the era of personalized medicine. The major topics of the meeting were assessment of the role of pathology in personalized medicine, its future profile among other biomedical disciplines with an interest in personalized medicine as well as the evolution of companion diagnostics. The relevance of novel technologies for genome analysis in clinical practice was discussed. The participants recognize that there should be more initiatives taken by the pathology community in companion diagnostics and in the emerging field of next-generation sequencing and whole genome analysis. The common view of the participants was that the pathology community has to be mobilized for stronger engagement in the future of personalized medicine. Pathologists should be aware of the challenges and the analytical opportunities of the new technologies. Challenges of clinical trial design as well as insurance and reimbursement questions were addressed. The pathology community has the responsibility to lead medical colleagues into embracing this new area of genomic medicine. Without this effort, the discipline of pathology risks losing its key position in molecular tissue diagnostics.
Indexed as
Identifiers
22143935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.